CPHI Milan 2024: Highlighting the Benefits of Integrated Services

When outsourced services are required, bio/pharmaceutical companies can take a more traditional approach, whereby they split their program up and use one or more contract development and manufacturing organizations (CDMOs) in addition to a separate contract research organization (CRO), or they can choose an integrated model. “[The term] ‘integrated services’ has multiple meanings,” specifies Kevin Li, MBA, chief marketing officer at BioDuro-Sundia.

Integrated services can be viewed as horizontal, in that a partner would provide services covering discovery to development and commercial manufacturing, Li notes. If you then look vertically, it is possible to also integrate the medicinal chemistry, biology, and drug metabolism and pharmacokinetics into the discovery phase and through development, he adds. “One side can handle both drug substance and drug product, and one side can handle the pre-formulation, formulation development, until commercial manufacturing, everything in one side,” Li says, “so that integrated solution can really help customers to accelerate their innovation through multiple benefits.”

Benefits of using an integrated solution include the convenience of material transfer among different teams, the information sharing, and the quality system, which can help to speed up the program timescale, Li explains. “One of the biggest benefits is [that it is] very simple to manage the vendors, because it's very difficult and time consuming to manage multiple vendors, and if you do integrate the program with one vendor through our integrated or dedicated project manager, that's much easier, simpler to manage the process to avoid any potential interruptions.”

Click above to listen to the full interview captured on the show floor at CPHI Milan

BioDuro-Sundia exhibited at CPHI Milan, which took place on Oct. 8–10, 2024.

About the speaker

Kevin Li, MBA, is the chief marketing officer at BioDuro-Sundia, and has more than 15 years of industry experience. Prior to working at BioDuro-Sundia, Kevin led the global marketing and public relations teams across the US and China for the WuXi Chemistry division at WuXi AppTec. Additionally, Kevin led the global marketing efforts for the Oral Dose, Rx, and OTC Softgel business units at Catalent Pharma Solutions. Earlier still, Kevin worked in marketing for ConvaTec and Becton, Dickinson and Company, and held scientist roles at Pfizer (Hospira) and Abbott (AbbVie). Kevin studied chemistry at Northwestern University and business administration at Duke University.